Patients' attitudes and preferences toward delayed disease progression in the absence of improved survival.

Prolongation of time to progression was not universally valued. Treatments that impact negatively on quality of life were not preferred by most patients for PFS gains alone. Implications for individual decision making, policy, and trials research are discussed.